gip glp-1 dual agonist and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Cardiorenal Outcomes With GLP-1 vs.

The current medical consensus, reflected in obesity medicine guidelines from organizations such as the American Gastroenterological Association and Obesity Medicine Association, treats obesity as a chronic disease requiring long-term pharmacological management in most cases, similar to hypertension or hyperlipidemia

Thus, Astaxanthin+l Glutathione+lutein is an effective supplemental treatment for a range of eye diseases

W.BeattyG

Lancet 357 , 752756 (2001)

Adults may generally qualify if they have a BMI of 30 or higher, which meets the medical definition of obesity, or a BMI of 27 or higher with at least one weight-related medical condition